EGFR K708R

CI-VAR-00002171Explore in graph →CIViC 3490

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
EGFR K708R	Cetuximab + PanitumumabSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID9659 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR K708R showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
Malignant Neoplasm1
EGFR K708R	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9649 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR K708R. NIH-3T…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
EGFR K708R	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9641 Ba/F3 cells transfected with EGFR K708R had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic